Literature DB >> 33866514

Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Sylvia L Asa1.   

Abstract

Detailed analysis of cytodifferentiation and hormone production has classified pituitary neuroendocrine tumors (PitNETs) in a formal system that reflects the lineage differentiation of nontumorous adenohypophysial cells as well as subtypes of tumors that have predictive value. In addition, tumors composed of cells that lack terminal differentiation are well characterized. To comply with the proposal to create an overarching classification of neuroendocrine neoplasia, these tumors are now called PitNETs rather than adenomas. The next important step will be to relinquish the term "pituitary carcinoma" for metastatic PitNETs that remain well differentiated, and to alter the terminology used for tumors that are not terminally differentiated to reflect only their immature lineage. The existence of mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) similar to those at other body sites is proven by mixed craniopharyngiomas with PitNETs. As with other NETs, these neoplasms should be reported with synoptic data that guide completeness of reporting. A formal system of grading should be created, but not only based on proliferation, as these tumors have shown the prognostic value of cytodifferentiation. A formal system of staging should also be devised to complement grade in the thorough and accurate diagnosis of tumors that arise from adenohypophysial cells.

Entities:  

Keywords:  Cytodifferentiation; Neuroendocrine tumor; Pituitary adenoma; Pituitary neuroendocrine tumor

Year:  2021        PMID: 33866514     DOI: 10.1007/s12022-021-09678-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  32 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

Authors:  S L Asa; O Casar-Borota; P Chanson; E Delgrange; P Earls; S Ezzat; A Grossman; H Ikeda; N Inoshita; N Karavitaki; M Korbonits; E R Laws; M B Lopes; N Maartens; I E McCutcheon; O Mete; H Nishioka; G Raverot; F Roncaroli; W Saeger; L V Syro; A Vasiljevic; C Villa; A Wierinckx; J Trouillas
Journal:  Endocr Relat Cancer       Date:  2017-04       Impact factor: 5.678

Review 3.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 4.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 5.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

Authors:  Gerald Raverot; Pia Burman; Ann McCormack; Anthony Heaney; Stephan Petersenn; Vera Popovic; Jacqueline Trouillas; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2017-10-18       Impact factor: 6.664

6.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

Review 7.  Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations.

Authors:  Giovanna Finzi; Michele Cerati; Alessandro Marando; Cesare Zoia; Fabio Ferreli; Giustino Tomei; Paolo Castelnuovo; Stefano La Rosa; Carlo Capella
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

8.  P53 gene mutations in pituitary carcinomas.

Authors:  Yoshinori Tanizaki; Long Jin; Bernd W Scheithauer; Kalman Kovacs; Federico Roncaroli; Ricard V Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

9.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

Authors:  Ann McCormack; Olaf M Dekkers; Stephan Petersenn; Vera Popovic; Jacqueline Trouillas; Gerald Raverot; Pia Burman
Journal:  Eur J Endocrinol       Date:  2018-01-12       Impact factor: 6.664

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  3 in total

1.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

Review 2.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

Review 3.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Authors:  Ozgur Mete; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2022-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.